The U.S. Food and Drug Administration has given its first nod to a molecular test developed by Abbott Laboratories for the Zika virus for use to test whole blood. This expands upon an existing use of the test from the Abbott Park, Ill., company; it had already received emergency use authorization for use to test serum, plasma and urine.